A Computational Method to Classify Variants of Uncertain Significance Using Functional Assay Data with Application to BRCA1

被引:46
作者
Iversen, Edwin S., Jr. [1 ]
Couch, Fergus J. [2 ]
Goldgar, David E. [3 ]
Tavtigian, Sean V. [4 ]
Monteiro, Alvaro N. A. [5 ]
机构
[1] Duke Univ, Dept Stat Sci, Durham, NC 27708 USA
[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[3] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT USA
[4] Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT USA
[5] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Risk Assessment Detect & Intervent Program, Tampa, FL 33612 USA
关键词
UNKNOWN CLINICAL-SIGNIFICANCE; DNA-SEQUENCE VARIANTS; MISSENSE SUBSTITUTIONS; CANCER-RISK; CLASSIFICATION; MUTATIONS; BREAST; DISTRIBUTIONS;
D O I
10.1158/1055-9965.EPI-10-1214
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Besides revealing cancer predisposition variants or the absence of any changes, genetic testing for cancer predisposition genes can also identify variants of uncertain clinical significance (VUS). Classifying VUSs is a pressing problem, as ever more patients seek genetic testing for disease syndromes and receive noninformative results from those tests. In cases such as the breast and ovarian cancer syndrome in which prophylactic options can be severe and life changing, having information on the disease relevance of the VUS that a patient harbors can be critical. Methods: We describe a computational approach for inferring the disease relevance of VUSs in disease genes from data derived from an in vitro functional assay. It is based on a Bayesian hierarchical model that accounts for sources of experimental heterogeneity. Results: The functional data correlate well with the pathogenicity of BRCA1 BRCT VUSs, thus providing evidence regarding pathogenicity when family and genetic data are absent or uninformative. Conclusions: We show the utility of the model by using it to classify 76 VUSs located in the BRCT region of BRCA1. The approach is both sensitive and specific when evaluated on variants previously classified using independent sources of data. Although the functional data are very informative, they will need to be combined with other forms of data to meet the more stringent requirements of clinical application. Impact: Our work will lead to improved classification of VUSs and will aid in the clinical decision making of their carriers. Cancer Epidemiol Biomarkers Prev; 20(6); 1078-88. (C)2011 AACR.
引用
收藏
页码:1078 / 1088
页数:11
相关论文
共 30 条
[11]   Integrated evaluation of DNA sequence variants of unknown clinical significance:: Application to BRCA1 and BRCA2 [J].
Goldgar, DE ;
Easton, DF ;
Deffenbaugh, AM ;
Monteiro, ANA ;
Tavtigian, SV ;
Couch, FJ .
AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 75 (04) :535-544
[12]   Population-calibrated gene characterization: Estimating age at onset distributions associated with cancer genes [J].
Iversen, ES ;
Chen, SN .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2005, 100 (470) :399-409
[13]  
Jeffreys H., 1998, THEORY PROBABILITY
[14]   BAYES FACTORS [J].
KASS, RE ;
RAFTERY, AE .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1995, 90 (430) :773-795
[15]   BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications [J].
Kurian, Allison W. .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (01) :72-78
[16]   Comprehensive Analysis of Missense Variations in the BRCT Domain of BRCA1 by Structural and Functional Assays [J].
Lee, Megan S. ;
Green, Ruth ;
Marsillac, Sylvia M. ;
Coquelle, Nicolas ;
Williams, R. Scott ;
Yeung, Telford ;
Foo, Desmond ;
Hau, D. Duong ;
Hui, Ben ;
Monteiro, Alvaro N. A. ;
Glover, J. N. Mark .
CANCER RESEARCH, 2010, 70 (12) :4880-4890
[17]   WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility [J].
Lunn, DJ ;
Thomas, A ;
Best, N ;
Spiegelhalter, D .
STATISTICS AND COMPUTING, 2000, 10 (04) :325-337
[18]   A STRONG CANDIDATE FOR THE BREAST AND OVARIAN-CANCER SUSCEPTIBILITY GENE BRCA1 [J].
MIKI, Y ;
SWENSEN, J ;
SHATTUCKEIDENS, D ;
FUTREAL, PA ;
HARSHMAN, K ;
TAVTIGIAN, S ;
LIU, QY ;
COCHRAN, C ;
BENNETT, LM ;
DING, W ;
BELL, R ;
ROSENTHAL, J ;
HUSSEY, C ;
TRAN, T ;
MCCLURE, M ;
FRYE, C ;
HATTIER, T ;
PHELPS, R ;
HAUGENSTRANO, A ;
KATCHER, H ;
YAKUMO, K ;
GHOLAMI, Z ;
SHAFFER, D ;
STONE, S ;
BAYER, S ;
WRAY, C ;
BOGDEN, R ;
DAYANANTH, P ;
WARD, J ;
TONIN, P ;
NAROD, S ;
BRISTOW, PK ;
NORRIS, FH ;
HELVERING, L ;
MORRISON, P ;
ROSTECK, P ;
LAI, M ;
BARRETT, JC ;
LEWIS, C ;
NEUHAUSEN, S ;
CANNONALBRIGHT, L ;
GOLDGAR, D ;
WISEMAN, R ;
KAMB, A ;
SKOLNICK, MH .
SCIENCE, 1994, 266 (5182) :66-71
[19]   Genetic testing in an ethnically diverse cohort of high-risk women -: A comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry [J].
Nanda, R ;
Schumm, LP ;
Cummings, S ;
Fackenthal, JD ;
Sveen, L ;
Ademuyiwa, F ;
Cobleigh, M ;
Esserman, L ;
Lindor, NM ;
Neuhausen, SL ;
Olopade, OI .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (15) :1925-1933
[20]   Classification of BRCA1 missense variants of unknown clinical significance [J].
Phelan, CM ;
Dapic, V ;
Tice, B ;
Favis, R ;
Kwan, E ;
Barany, F ;
Manoukian, S ;
Radice, P ;
van der Luijt, RB ;
van Nesselrooij, BPM ;
Chenevix-Trench, G ;
Caldes, T ;
de La Hoya, M ;
Lindquist, S ;
Tavtigian, SV ;
Goldgar, D ;
Borg, Å ;
Narod, SA ;
Monteiro, ANA .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (02) :138-146